OM
EDIT icon

Opaleye Management’s Editas Medicine EDIT Stock Holding History

Opaleye Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Buy
3,861,930
+1,934,933
+100% +$5.66M 1.13% 24
2026
Q1 		$4.76M Buy
+1,926,997
New +$4.08M 0.63% 31

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Opaleye Management's EDIT Position: Q2 2026 in Review

Opaleye Management increased its Editas Medicine (EDIT) stake by 100% in Q2 2026, buying an estimated $5.66M and bringing the position to 3,861,930 shares worth $12.5M. The position accounts for 1.13% of the portfolio, ranked #24.

Opaleye Management first reported a position in EDIT in Q1 2026 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Opaleye Management held 3,861,930 shares of Editas Medicine worth $12.5M as of Q2 2026.
  • Opaleye Management bought 1,934,933 Editas Medicine shares in Q2 2026, an estimated $5.66M.
  • Editas Medicine made up 1.13% of Opaleye Management's portfolio in Q2 2026, its #24 holding.
  • Opaleye Management first reported a position in Editas Medicine in Q1 2026 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.